Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/II Study of Anti-CD19 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma
Brief Summary: The primary objective of this phase I study is to evaluate the safety and to establish the recommended dose of CD19-CART01 infused in pediatric patients affected by relapsed/refractory B-ALL or NHL with measurable Bone Marrow (BM) involvement. The phase II extension is aimed at testing the efficacy of the treatment at the optimal dose defined in the phase I.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Biological: lisocabtagene maraleucel | Intervention Type: BIOLOGICAL; Name: lisocabtagene maraleucel; Assigned to Arm(s): Treatment
B: Arm Label: CD19-CART01; Type: EXPERIMENTAL; Interventions: Biological: CD19-CAR T cell | Intervention Type: BIOLOGICAL; Name: CD19-CAR T cell; Assigned to Arm(s): CD19-CART01
C: Arm Label: Arm A: JCAR017 in combination with Durvalumab; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: Durvalumab | Arm Label: Arm B: JCAR017 in combination with CC-122; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: CC-122 | Arm Label: Arm C: JCAR017 in combination with CC-220; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: CC-220 | Arm Label: Arm D: JCAR017 in combination with Ibrutinib; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: Ibrutinib | Arm Label: Arm E: JCAR017 in combination with relatlimab and/or nivolumab; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: Relatlimab, Drug: Nivolumab | Arm Label: Arm F: JCAR017 in combination with CC-99282; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: CC-99282 | Intervention Type: BIOLOGICAL; Name: JCAR017; Assigned to Arm(s): Arm A: JCAR017 in combination with Durvalumab, Arm B: JCAR017 in combination with CC-122, Arm C: JCAR017 in combination with CC-220, Arm D: JCAR017 in combination with Ibrutinib, Arm E: JCAR017 in combination with relatlimab and/or nivolumab, Arm F: JCAR017 in combination with CC-99282 | Intervention Type: DRUG; Name: Durvalumab; Assigned to Arm(s): Arm A: JCAR017 in combination with Durvalumab | Intervention Type: DRUG; Name: CC-122; Assigned to Arm(s): Arm B: JCAR017 in combination with CC-122 | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm D: JCAR017 in combination with Ibrutinib | Intervention Type: DRUG; Name: CC-220; Assigned to Arm(s): Arm C: JCAR017 in combination with CC-220 | Intervention Type: DRUG; Name: Relatlimab; Assigned to Arm(s): Arm E: JCAR017 in combination with relatlimab and/or nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm E: JCAR017 in combination with relatlimab and/or nivolumab | Intervention Type: DRUG; Name: CC-99282; Assigned to Arm(s): Arm F: JCAR017 in combination with CC-99282
D: Arm Label: Human CD19 targeted T Cells Injection; Type: EXPERIMENTAL; Interventions: Drug: Human CD19 targeted T Cells Injection | Intervention Type: DRUG; Name: Human CD19 targeted T Cells Injection; Assigned to Arm(s): Human CD19 targeted T Cells Injection

Answer: B